Cantor Fitzgerald’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Cantor Fitzgerald’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50,205	Closed	-$147K	–	326
2024 Q2	$147K	Sell	50,205 -25,000	-33%	-$68.4K	0.03%	152
2024 Q1	$240K	Buy	75,205 +25,000	+50%	+$83.4K	0.06%	130
2023 Q4	$169K	Buy	+50,205	New	+$129K	0.03%	142
2022 Q4	–	Sell	-45,205	Closed	-$160K	–	780
2022 Q3	$160K	Hold	45,205	–	–	﹤0.01%	614
2022 Q2	$117K	Buy	45,205 +15,000	+50%	+$41.7K	﹤0.01%	674
2022 Q1	$135K	Buy	30,205 +5,000	+20%	+$22.5K	0.01%	279
2021 Q4	$172K	Buy	+25,205	New	+$172K	0.01%	279

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Cantor Fitzgerald's PSTX Position: Q3 2024 in Review

Cantor Fitzgerald sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2024, closing a stake of 50,205 shares — an estimated $147K sold.

Cantor Fitzgerald first reported a position in PSTX in Q4 2021 and held it in 7 quarters. The position peaked at $240K in Q1 2024. 96 funds tracked by Wall St. Rank hold PSTX as of Q3 2024.

Cantor Fitzgerald reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Cantor Fitzgerald sold 50,205 Poseida Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $147K.
Cantor Fitzgerald first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Cantor Fitzgerald's Poseida Therapeutics, Inc. Common Stock position peaked at $240K in Q1 2024.
96 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Cantor Fitzgerald's 13F filing for Q3 2024, filed 14 Nov 2024.